Termination of systemic immunity in the presence of intraocular tumors: Influence of ocular immune privilege on tumor vaccines

Current Eye Research

Volumn 31, Issue 1, 2006, Pages 43-55

  Chen, Peter W ^a   Ksander, Bruce R ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Immune privilege; Ocular tumor; Vaccine

Indexed keywords

B7 ANTIGEN; INTERLEUKIN 12; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTERIOR EYE CHAMBER; ARTICLE; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; FEMALE; IMMUNITY; IMMUNIZATION; INTRAOCULAR TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROVOCATION TEST; SUBCUTANEOUS TISSUE TUMOR; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR CELL; TUMOR LOCALIZATION;

ANIMALS; ANTERIOR CHAMBER; ANTIGENS, CD80; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; EYE NEOPLASMS; FEMALE; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; IMMUNIZATION; INTERLEUKIN-12; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTES, TUMOR-INFILTRATING; MASTOCYTOMA; MICE; MICE, INBRED DBA; MICE, SCID; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 31544468439     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680500477339     Document Type: Article

References (40)

1. Taylor A. A review of the influence of aqueous humor on immunity. Ocul Immunol Inflamm. 2003;11:231-241.
2. Green DR, Ferguson TA. The role of Fas ligand in immune privilege. Nature Rev Mol Cell Biol. 2001;2:917-924.
3. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3:879-889.
4. Kaplan HJ, Streilein JW. Immune response to immunization via the anterior chamber of the eye. I. Lymphocyte-induced immune deviation. J Immunol. 1977;118:809-814.
5. Wilbanks GA, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID). I. Evidence that an antigen specific ACAID-inducing cell associated signal exists in the peripheral blood. J Immunol. 1991;146:2610-2617.
6. Wilbanks GA, Mammolenti MM, Streilein JW. Studies on the induction of anterior chamber-associated immune deviation (ACAID). II. Eye-derived cells participate in generating blood borne signals that induce ACAID. J Immunol. 1991;146:3018-3024.
7. Ksander BR, Streilein JW. Failure of precursor cytotoxic T cells to acquire direct cytotoxic function in immunologically privileged sites. J Immunol. 1990;145:2057-2063.
8. Ksander BR, Bando Y, Acevedo J, Streilein JW. Infiltration and accumulation of precursor cytotoxic T cells increase with time in progressively growing ocular tumors. Cancer Res. 1991;51:3153-3158.
9. Ksander BR, Mammolenti MM, Streilein JW. Termination of immune privilege in the anterior chamber of the eye when tumor-infiltrating lymphocytes acquire cytolytic function. Transplantation. 1991;52:128-133.
10. Mach N, Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol. 2000;12:571-575.
11. Antonia SJ. B7-1 gene-modified tumor cell vaccines. Curr Opin Mol Ther. 1999;1:50-56.
12. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol. 1995;13:251-276.
13. Seder RA, Gazzinelli R, Sher A, Paul WE. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA. 1993;90:10188-10192.
14. Vesosky B, Hurwitz AA. Modulation of costimulation to enhance tumor immunity. Cancer Immunol Immunother. 2003;52:663-669.
15. Chen PW, Geer DC, Podack ER, Ksander BR. Tumor cells transfected with B7-1 and interleukin 12 cDNA induce protective immunity. Ann NY Acad Sci. 1996;795:325-327.
16. Uyttenhove C, Maryanski J, Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med. 1983;157:1040-1052.
17. Maryanski JL, Van Snick J, Cerottini JC, Boon T. Immunologic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur J Immunol. 1982;12:401-406.
18. Boon T, Van Snick J, Van Pel A, et al. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med. 1994;152:1184-1193.
19. + T cells matter in tumor immunity. Int Rev Immunol. 2003;22:113-140.
20. Zhou G, Lu Z, McCadden JD, et al. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med. 2004;200:1581-1592.
21. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother. 2004;53:844-854.
22. Portielje JE, Gratama JW, van Ojik HH, et al. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother. 2003;52:133-144.
23. Hull GW, Mccurdy MA, Nasu Y, et al. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin Cancer Res. 2000;6:4101-4109.
24. Pulaski BA, Clements VK, Pipeling MR, Ostrand-Rosenberg S. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol Immunother. 2000;49:34-45.
25. Carroll MW, Overwijk WW, Surman DR, Tsung K, Moss B, Restifo NP. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. J Natl Cancer Inst. 1998;90:1881-1887.
26. Zitvogel L, Robbins PD, Storkus WJ, et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol. 1996;26:1335-1341.
27. Niederkorn JY, Streilein JW. Intracamerally induced concomitant immunity: mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge. J Immunol. 1983;131:2587-2594.
28. Ksander BR, Streilein JW. Immune privilege to MHC disparate tumor grafts in the anterior chamber of the eye I. Quantitative analysis of intraocular tumor growth and the corresponding delayed hypersensitivity response. Transplantation. 1989;47:661-667.
29. Niederkorn JY, Streilein JW, Kripke ML. Promotion of syngeneic intraocular tumor growth in mice by anterior chamber-associated immune deviation J Natl Cancer Inst. 1983;71:193-199.
30. Ma D, Alizadeh H, Comerford SA, et al. Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes. Curr Eye Res. 1994;13:361-369.
31. Ma D, Comerford S, Bellingham D, et al. Capacity of simian virus 40 T antigen to induce self-tolerance but not immunological privilege in the anterior chamber of the eye. Transplantation. 1994;57:718-725.
32. Schurmans LHRM, den Boer A Th, Diehl L, et al. Successful immunotherapy of an intraocular tumor in mice. Cancer Res. 1999;59:5250-5254.
33. Borbulevych OY, Baxter TK, Yu Z, et al. Increased immunogenicity of an anchor-modified tumor-associated antigen is due ot the enhanced stability of the peptide / MHC complex: implications for vaccine design. J Immunol. 2005;174:4812-4820.
34. Lazoura E, Apostolopoulos V. Rational peptide-based vaccine design for cancer immunotherapeutic applications. Curr Med Chem. 2005;12:629-639.
35. Romero P, Valmori D, Pittet MJ, et al. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev. 2002;188:81-96.
36. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137-148.
37. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-360.
38. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-998.
39. Kosiewicz MM, Okamoto S, Miki S, et al. Imposing deviant immunity on the presensitized state. J Immunol. 1994;153:2962-2973.
40. Streilein JW, Niederkorn JY, Shadduck JA. Systemic immune unresponsiveness induced in adult mice by anterior chamber presentation of minor histocompatibility antigens. J Exp Med. 1980;152:1121-1125.